BMC Neurology

official impact factor 2.80
Search for
Advanced search
BMC Neurology
Tools
Share this article
Open Access Highly Access Email this article to a friend

The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial

Kenneth Rockwood*, Sherri Fay, Mary Gorman, Daniel Carver and Janice E Graham

BMC Neurology 2007, 7:26 doi:10.1186/1471-2377-7-26

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.